We can’t show the full text here under this license.
Abstract
A 47-year-old male experienced isolated thrombocytopenia of 6000/µL after increasing tirzepatide dosage to 12.5 mg.
- The patient developed an ecchymotic, petechial rash within a week of the dosage increase.
- Secondary causes of thrombocytopenia were ruled out, suggesting a direct association with tirzepatide.
- Treatment with intravenous immunoglobulin (IVIG) and steroids led to a return of platelet counts to baseline.
- Findings indicate a potential immune-mediated mechanism for severe thrombocytopenia linked to tirzepatide.
- Clinical awareness of this rare side effect may help prevent serious complications.
Simplified